Key result
Echocardiographically defined pulmonary hypertension resolved in 59% of patients following kidney transplantation, with persistent PH showing a lower 3-year survival with a functioning graft compared to resolved PH (76.0% vs 94.4%), though this difference was not significant at 5 years.
Why the study?
Does pretransplant pulmonary hypertension resolve following kidney transplantation, and is its persistence associated with worse clinical outcomes?
Cohort (n=115)
Yes
Does pretransplant pulmonary hypertension resolve following kidney transplantation, and is its persistence associated with worse clinical outcomes?
Absolute Event Rate: 76% vs 94.4%
p-value: p=0.04
Pretransplant pulmonary hypertension resolves in a majority of patients after kidney transplantation, and its persistence does not clearly worsen long-term mortality or graft survival.
Supports expectant management of pretransplant PH after kidney transplant; leaves open whether persistence warrants intervention in prospective studies.
The post 3 kidney transplant course of pretransplant echocardiographically-defined pulmonary hypertension (PH) was reviewed in 115 patients. Of these 61 patients (the largest cohort reported to date), underwent 160 "for indication" echocardiograms posttransplant (mean echocardiograms per patient: 2.6 ± 2.3). Patients undergoing posttransplant echocardiograms demonstrated greater risks for worse outcomes than those without posttransplant echocardiograms; however, there was no difference in mortality, death-censored graft failure or the composite of death or graft failure between these two groups. Of patients tested, 36 (59%) showed resolution of PH at a median of 37.5 months. Six patients (16.7%) in whom PH resolved (at a median of 29 months), experienced recurrence of PH after an interval of 48 months. No pretransplant demographic or echocardiographic characteristics distinguished those in whom PH persisted versus resolved. Though there was no difference in the risk for mortality or death-censored graft loss between the two groups at 3 and 5 years, there was a higher risk for the composite of mortality or graft loss at three but not at five years in the group with persistent PH. In conclusion, echocardiographically defined PH resolved in 59% of patients following kidney transplantation; but irrespective of resolution there was no clear association with worse outcome.
No takes yet. Share an insight, caveat, or question.
Frost et al. (2021) conducted a cohort in Pretransplant pulmonary hypertension in kidney transplant candidates (n=115). Persistent pulmonary hypertension post-transplantation vs. Resolved pulmonary hypertension post-transplantation was evaluated on Survival with a functioning graft at 3 years (p=0.04). Echocardiographically defined pulmonary hypertension resolved in 59% of patients following kidney transplantation, with persistent PH showing a lower 3-year survival with a functioning graft compared to resolved PH (76.0% vs 94.4%), though this difference was not significant at 5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: